Combined vascular endothelial growth factor-A and fibroblast growth factor 4 gene transfer improves wound healing in diabetic mice
Authors:
- Agnieszka JazwaAJAgnieszka Jazwa
- Paulina KucharzewskaPKPaulina Kucharzewska
- Justyna LejaJLJustyna Leja
- Anna ZagorskaAZAnna Zagorska
- Aleksandra SierpniowskaASAleksandra Sierpniowska
- Jacek StepniewskiJSJacek Stepniewski
- Magdalena KozakowskaMKMagdalena Kozakowska
- Hevidar TahaHTHevidar Taha
- Takahiro OchiyaTOTakahiro Ochiya
- Rafal DerlaczRDRafal Derlacz
- Elisa VahakangasEVElisa Vahakangas
- Seppo Yla-HerttualaSeppo Yla-Herttuala
Open Access
- 30 August 2010
- journal article
- Published by Springer Nature in Genetic Vaccines and Therapy
- Vol. 8 (1) , 6
Abstract
Background: Impaired wound healing in diabetes is related to decreased production of growth factors. Hence, gene therapy is considered as promising treatment modality. So far, efforts concentrated on single gene therapy with particular emphasis on vascular endothelial growth factor-A (VEGF-A). However, as multiple proteins are involved in this process it is rational to test new approaches. Therefore, the aim of this study was to investigate whether single AAV vector-mediated simultaneous transfer of VEGF-A and fibroblast growth factor 4 (FGF4) coding sequences will improve the wound healing over the effect of VEGF-A in diabetic (db/db) mice. Methods: Leptin receptor-deficient db/db mice were randomized to receive intradermal injections of PBS or AAVs carrying β-galactosidase gene (AAV-LacZ), VEGF-A (AAV-VEGF-A), FGF-4 (AAV-FGF4-IRES-GFP) or both therapeutic genes (AAV-FGF4-IRES-VEGF-A). Wound healing kinetics was analyzed until day 21 when all animals were sacrificed for biochemical and histological examination. Results: Complete wound closure in animals treated with AAV-VEGF-A was achieved earlier (day 19) than in control mice or animals injected with AAV harboring FGF4 (both on day 21). However, the fastest healing was observed in mice injected with bicistronic AAV-FGF4-IRES-VEGF-A vector (day 17). This was paralleled by significantly increased granulation tissue formation, vascularity and dermal matrix deposition. Mechanistically, as shown in vitro, FGF4 stimulated matrix metalloproteinase-9 (MMP-9) and VEGF receptor-1 expression in mouse dermal fibroblasts and when delivered in combination with VEGF-A, enhanced their migration. Conclusion: Combined gene transfer of VEGF-A and FGF4 can improve reparative processes in the wounded skin of diabetic mice better than single agent treatment.Keywords
This publication has 45 references indexed in Scilit:
- Stabilization of HIF-1α is critical to improve wound healing in diabetic miceProceedings of the National Academy of Sciences, 2008
- Receptor Specificity of the Fibroblast Growth Factor FamilyJournal of Biological Chemistry, 2006
- How accurately can we discriminate G-protein-coupled receptors as 7-tms TM protein sequences from other sequences?Biochemical and Biophysical Research Communications, 2005
- Topical Vascular Endothelial Growth Factor Accelerates Diabetic Wound Healing through Increased Angiogenesis and by Mobilizing and Recruiting Bone Marrow-Derived CellsThe American Journal of Pathology, 2004
- Detection of spatial localization of Hst-1/Fgf-4 gene expression in brain and testis from adult miceOncogene, 2000
- Heparin Differentially Regulates the Interaction of Fibroblast Growth Factor-4 with FGF Receptors 1 and 2Biochemical and Biophysical Research Communications, 1999
- Fibroblast growth factors and their receptorsBiochemistry and Cell Biology, 1997
- Platelet-derived growth factor levels in wounds of diabetic ratsLife Sciences, 1995
- Regulatory sequences required for hst‐1 expression in embryonal carcinoma cellsFEBS Letters, 1994
- Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cellsBiochemical and Biophysical Research Communications, 1991